Clinical trial
Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII)
NCT00925821 is registered in ClinicalTrials.gov with Wuerzburg University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII)
- Lead sponsor
- Wuerzburg University Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- Not reported
- Enrollment
- 146 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.